دورية أكاديمية
Long-term prolonged-release tacrolimus outcomes in living donor kidney transplantation: The Japan Academic Consortium of Kidney Transplantation study-II.
| العنوان: | Long-term prolonged-release tacrolimus outcomes in living donor kidney transplantation: The Japan Academic Consortium of Kidney Transplantation study-II. |
|---|---|
| المؤلفون: | Okumi M; Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan.; Department of Urology, Tokyo Women's Medical University, Tokyo, Japan., Omoto K; Department of Urology, Tokyo Women's Medical University, Tokyo, Japan., Shimizu T; Department of Urology, Toda Chuo General Hospital, Saitama, Japan., Shirakawa H; Department of Urology, Ohkubo Hospital, Tokyo, Japan., Unagami K; Department of Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan., Lee T; Astellas Pharma Inc., Tokyo, Japan., Ishida H; Department of Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan., Tanabe K; Center for Robotics and Organ Transplantation, Shonan Kamakura General Hospital, Kanagawa, Japan., Takagi T; Department of Urology, Tokyo Women's Medical University, Tokyo, Japan. |
| المصدر: | International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2023 May; Vol. 30 (5), pp. 483-491. Date of Electronic Publication: 2023 Feb 16. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Science Asia Country of Publication: Australia NLM ID: 9440237 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1442-2042 (Electronic) Linking ISSN: 09198172 NLM ISO Abbreviation: Int J Urol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Carlton South, Vic. : Blackwell Science Asia Original Publication: Tokyo ; New York : Churchill Livingstone, c1994- |
| مواضيع طبية MeSH: | Kidney Transplantation*/adverse effects , Diabetes Mellitus*/epidemiology , Diabetes Mellitus*/chemically induced, Humans ; Aged ; Tacrolimus/adverse effects ; Retrospective Studies ; Living Donors ; Japan/epidemiology ; Graft Rejection/epidemiology ; Graft Rejection/prevention & control ; Immunosuppressive Agents/adverse effects ; Graft Survival |
| مستخلص: | Objectives: To evaluate the 10-year efficacy and safety of a prolonged-release tacrolimus-based combination immunosuppressive regimen on longer-term outcomes in living donor kidney transplantation. Methods: Data from Japanese living donor kidney transplant recipients (n = 410) maintained on continuous prolonged-release tacrolimus-based immunosuppression from 2009-2013 were analyzed with a median follow-up of 9.9 years. Results: A prolonged-release, tacrolimus-based combination regimen provided death-censored graft failure and all-cause death rates at 10 years of 7.0% and 6.8%, respectively. In multivariable analyses, acute and chronic rejection and 'throughout' (new-onset plus preexisting) diabetes mellitus were risk factors for death-censored graft failure. Recipient age ≥ 65 years, throughout diabetes mellitus and malignancy were common risk factors for all-cause death. Throughout diabetes mellitus was the most common risk factor for both death-censored graft failure and all-cause death. Additional analyses showed 10-year cumulative rates of death-censored graft failure were 14.0% and 5.4% for recipients with or without preexisting diabetes mellitus, respectively (log-rank test: p = 0.009). All-cause death rates were 12.7% and 5.4% in the preexisting and non-diabetes mellitus groups, respectively (log-rank test: p = 0.023). Conclusions: In this real-world, retrospective, living donor kidney transplantation study, a prolonged-release tacrolimus-based immunosuppressive combination regimen provided 10-year death-censored graft failure rates of 14.0% and 5.4% in diabetes mellitus and non-diabetes mellitus patients, respectively; Similarly, 10-year all-cause death rates were 12.7% and 5.4% in diabetes mellitus and non-diabetes mellitus patients, respectively. To our knowledge, the data in this study are the first to provide 10-year transplant outcomes in living donor kidney transplant recipients under prolonged-release tacrolimus-based regimen. (© 2023 The Japanese Urological Association.) |
| References: | Okumi M, Unagami K, Furusawa M, Kakuta Y, IIzuka J, Takagi T, et al. Once-daily vs twice-daily tacrolimus for de novo living kidney transplantation patients including ABO/HLA compatible and incompatible: a randomized trial. Clin Transplant. 2018;32:e13423. Okumi M, Unagami K, Kakuta Y, Ochi A, Takagi T, Ishida H, et al. Elderly living donor kidney transplantation allows worthwhile outcomes: the Japan academic consortium of kidney transplantation study. Int J Urol. 2017;24:833-40. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532-9. Hill CJ, Fogarty DG. Changing trends in end-stage renal disease due to diabetes in the United Kingdom. J Ren Care. 2012;38(Suppl 1):12-22. Yang WC, Hwang SJ, Taiwan Society of N. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. Nephrol Dial Transplant. 2008;23(12):3977-82. Wakai K, Nakai S, Kikuchi K, Iseki K, Miwa N, Masakane I, et al. Trends in incidence of end-stage renal disease in Japan, 1983-2000: age-adjusted and age-specific rates by gender and cause. Nephrol Dial Transplant. 2004;19:2044-52. Okumi M, Unagami K, Hirai T, Shimizu T, Ishida H, Tanabe K, et al. Diabetes mellitus after kidney transplantation in Japanese patients: the Japan academic consortium of kidney transplantation study. Int J Urol. 2017;24:197-204. Okumi M, Toki D, Nozaki T, Shimizu T, Shirakawa H, Omoto K, et al. ABO-incompatible living kidney transplants: evolution of outcomes and immunosuppressive management. Am J Transplant. 2016;16:886-96. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009;32:3-107. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, et al. Diagnostic criteria for dyslipidemia. Executive summary of Japan atherosclerosis society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb. 2007;14:155-8. Pham PT, Pham PM, Pham SV, Pham PA, Pham PC. New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr Obes. 2011;4:175-86. Examination Committee of Criteria for 'Obesity Disease' in J, Japan Society for the Study of O. New criteria for 'obesity disease' in Japan. Circ J. 2002;66:987-92. Dekker FW, de Mutsert R, van Dijk PC, Zoccali C, Jager KJ. Survival analysis: time-dependent effects and time-varying risk factors. Kidney Int. 2008;74:994-7. Vatcheva KP, Lee M, McCormick JB, Rahbar MH. Multicollinearity in regression analyses conducted in epidemiologic studies. Epidemiology (Sunnyvale). 2016;6:227. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843. Chevallier E, Jouve T, Rostaing L, Malvezzi P, Noble J. Pre-existing diabetes and PTDM in kidney transplant recipients: how to handle immunosuppression. Expert Rev Clin Pharmacol. 2021;14:55-66. Yan F, Eshak ES, Shirai K, Dong JY, Muraki I, Tamakoshi A, et al. Soy intake and risk of type 2 diabetes among Japanese men and women: JACC study. Front Nutr. 2021;8:813742. Sharif A, Hecking M, De Vries AP, Porrini E, Hornum M, Rasoul-Rockenschaub S, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014;14:1992-2000. Taber DJ, Meadows HB, Pilch NA, Chavin KD, Baliga PK, Egede LE. Pre-existing diabetes significantly increases the risk of graft failure and mortality following renal transplantation. Clin Transplant. 2013;27:274-82. Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. Int J Clin Pract. 2006;60:1471-83. Imamura R, Nakazawa S, Yamanaka K, Kakuta Y, Tsutahara K, Taniguchi A, et al. Cumulative cancer incidence and mortality after kidney transplantation in Japan: a long-term multicenter cohort study. Cancer Med. 2021;10:2205-15. Shivaswamy V, Boerner B, Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev. 2016;37:37-61. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7:1506-14. Wan SS, Ying TD, Wyburn K, Roberts DM, Wyld M, Chadban SJ. The treatment of antibody-mediated rejection in kidney transplantation: an updated systematic review and meta-analysis. Transplantation. 2018;102:557-68. Tripepi G, Jager KJ, Dekker FW, Wanner C, Zoccali C. Bias in clinical research. Kidney Int. 2008;73:148-53. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129-40. |
| معلومات مُعتمدة: | 506-MA-3257 Astellas Pharma Inc. (Tokyo, Japan) |
| فهرسة مساهمة: | Keywords: calcineurin inhibitor; diabetic kidney disease; kidney transplantation; long-term outcomes; new-onset diabetes mellitus after transplantation; posttransplant diabetes mellitus; preexisting diabetes; prolonged-release tacrolimus |
| المشرفين على المادة: | WM0HAQ4WNM (Tacrolimus) 0 (Immunosuppressive Agents) |
| تواريخ الأحداث: | Date Created: 20230217 Date Completed: 20230519 Latest Revision: 20230711 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1111/iju.15163 |
| PMID: | 36798048 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1442-2042 |
|---|---|
| DOI: | 10.1111/iju.15163 |